Close menu




January 28th, 2021 | 10:23 CET

Steinhoff International, AdTiger, NEL: How to realize book profits

  • Investments
Photo credits: pixabay.com

Easy come easy go. That is how private investors feel time and again. Generating book profits is one thing, but securing them in the long term and turning them into a real trading success is quite another. We explain how it can be possible to realize profits with hot stocks, using Steinhoff International, AdTiger and NEL as examples.

time to read: 2 minutes | Author: Nico Popp
ISIN: KYG009701064 , NL0011375019 , NO0010081235

Table of contents:


    Steinhoff International: What gamblers have to endure

    Steinhoff International's stock has been a hot stock for several weeks. Since 2017, the Company has been embroiled in a legal battle. After accounting violations, it rained lawsuits against the Dutch Company with its operational headquarters in South Africa. In total, the lawsuits cover claims amounting to around EUR 8 billion. The Company itself wants to settle these partly in cash and partly in shares in Pepkor. Recently, Pepkor reported quarterly figures. These sent positive signals to gamblers around the penny stock Steinhoff International; if the offer is attractive, the probability of a settlement between the plaintiffs and the furniture group increases. The better the figures at Pepkor, the more likely plaintiffs will also settle with shares in the Company, so the thinking goes.

    But speculation on a settlement is by no means a foregone conclusion. First, there are several plaintiffs, and second, litigation per se is not a suitable environment for investments - too often, there are nasty surprises or an information advantage of professional investors. Yesterday, the Steinhoff share climbed from EUR 0.09 to EUR 0.13 within a few hours, only to correct back below the EUR 0.10 mark. Any gamblers who want to accompany this roller coaster ride should accept such fluctuations at least intraday. The exit should work with fixed limits and directly place these orders after purchasing a share on the market. In this way, the exit is guaranteed and there are no book profits.

    AdTiger: When does this Asian tiger start to jump?

    In contrast to highly hyped gambling stocks, investors can lay the foundation for later success with relatively unknown stocks at entry time. If small companies with an exciting business model can be discovered before the masses, a favorable entry price inevitably results in a lower risk. On the one hand, such stocks have a lower drop height, and, on the other hand, a "safety buffer" is quickly created on the market when more investors become aware of the respective story. The AdTiger share offers just such an investment story.

    The Company sees itself as an advertising platform that helps Chinese advertisers to place ads on the most popular networks. Specifically, AdTiger works with Facebook, Google, Yahoo and also TikTok. In addition to its involvement in China, AdTiger is now looking to India and expects further growth from their vast market. A key to more growth could also be the AdTensor software developed by AdTiger, which uses artificial intelligence and large amounts of data to control and optimize ad campaigns. AdTiger is currently valued at around EUR 80 million and has more than EUR 20 million in cash. As the value is presently trending cautiously sideways, investors can analyze the stock in peace and plan an entry in a considered manner.

    NEL: Here are the decisive marks

    Given the nervous price jumps of their favorite stock, shareholders of the hydrogen pioneer NEL are, at best, capable of deliberate action after the close of trading. Although NEL has gained more than 100% over a three-month period, the warning signals are increasing. Three times in the past four weeks, the stock has gone into reverse beyond the EUR 3.20 mark. Investors sitting on book profits in NEL but still believe in the share's long-term success can reduce part of their risk using partial sales given the large drop in the share price. The chart also provides guidance: While additional selling pressure is to be expected below the EUR 3 mark, the share could pick up speed again beyond the previous high from the beginning of January.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read